{"id":166,"date":"2010-08-13T00:43:06","date_gmt":"2010-08-13T00:43:06","guid":{"rendered":"http:\/\/alectos.com\/content\/?p=166"},"modified":"2010-08-13T00:43:06","modified_gmt":"2010-08-13T00:43:06","slug":"o-glcnac-sites-tau-antibody","status":"publish","type":"post","link":"https:\/\/alectos.com\/alectos-content\/index.php\/2010\/08\/13\/o-glcnac-sites-tau-antibody\/","title":{"rendered":"Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody"},"content":{"rendered":"<p>The microtubule-associated protein tau is known to be post-translationally modified by the addition of N-acetyl-D: -glucosamine monosaccharides to certain serine and threonine residues. These O-GlcNAc modification sites on tau have been challenging to identify due to the inherent complexity of tau from mammalian brains and the fact that the O-GlcNAc modification typically has substoichiometric occupancy. Here, we describe a method for the production of recombinant O-GlcNAc modified tau and, using this tau, we have mapped sites of O-GlcNAc on tau at Thr-123 and Ser-400 using mass spectrometry. We have also detected the presence of a third O-GlcNAc site on either Ser-409, Ser-412, or Ser-413. Using this information we have raised a rabbit polyclonal IgG antibody (3925) that detects tau O-GlcNAc modified at Ser-400. Further, using this antibody we have detected the Ser-400 tau O-GlcNAc modification in rat brain, which confirms the validity of this in vitro mapping approach. The identification of these O-GlcNAc sites on tau and this antibody will enable both in vivo and in vitro experiments designed to understand the possible functional roles of O-GlcNAc on tau.<\/p>\n<p>Source: <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20706749\" target=\"_blank\" rel=\"noopener\">Yuzwa, S.A. et al. <em>Amino Acids<\/em> <strong>40<\/strong>, 857-68 (2011).<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The microtubule-associated protein tau is known to be post-translationally modified  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[19],"tags":[18,20,24,28],"class_list":["post-166","post","type-post","status-publish","format-standard","hentry","category-publications","tag-oga","tag-sfu","tag-tau","tag-tau-antibody"],"_links":{"self":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/posts\/166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/comments?post=166"}],"version-history":[{"count":0,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/posts\/166\/revisions"}],"wp:attachment":[{"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/media?parent=166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/categories?post=166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alectos.com\/alectos-content\/index.php\/wp-json\/wp\/v2\/tags?post=166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}